Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

Haematologica. 2016 Dec;101(12):e492. doi: 10.3324/haematol.2016.156448.

¹ 5 Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria klaus.geissler@wienkav.at.
² Department of Laboratory Medicine, Medical University of Vienna, Austria.
³ Blood Transfusion Service for Upper Austria, Austrian Red Cross, Linz, Austria.
⁴ 3 Medical Department, Hanusch Hospital, Vienna, Austria.
⁵ Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria.

No abstract available

Keywords: CMML; JMML; RAS; ruxolitinib.

Publication types